Here, we analyzed the rates of the primary outcome – defined as best complete response (BCR) – and secondary outcomes defined as 12-month overall survival (OS) and best objective response (BOR) of CD19-positive leukemia or lymphoma patients treated with CD19 CAR T cells containing different hinge, transmembrane (TMD), and costimulatory domains. This evidence concerns the gene CD19 and leukemia.